Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2006-06-27
2006-06-27
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S001530, C424S130100, C424S178100, C424S133100, C424S134100, C424S001450, C424S139100, C424S136100, C424S144100, C424S085200, C514S002600, C514S012200, C530S388700, C530S387100, C530S389600
Reexamination Certificate
active
07067109
ABSTRACT:
Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.
REFERENCES:
patent: 4867962 (1989-09-01), Abrams
patent: 4925922 (1990-05-01), Byers et al.
patent: 4958009 (1990-09-01), Bjorn et al.
patent: 4980457 (1990-12-01), Jansen et al.
patent: 4981953 (1991-01-01), Barbieri et al.
patent: 5024834 (1991-06-01), Houston et al.
patent: 5057313 (1991-10-01), Shih et al.
patent: 5296467 (1994-03-01), Reutelingsperger
patent: 5344758 (1994-09-01), Krilis et al.
patent: 5627036 (1997-05-01), Reutelingsperger
patent: 5632986 (1997-05-01), Tait et al.
patent: 5632991 (1997-05-01), Gimbrone, Jr.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5658877 (1997-08-01), Tsao
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5677181 (1997-10-01), Parish
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5767298 (1998-06-01), Daleke
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5874081 (1999-02-01), Parish
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6020153 (2000-02-01), Hardman et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6043094 (2000-03-01), Martin et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6057435 (2000-05-01), Godowski et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6197278 (2001-03-01), Blankenberg et al.
patent: 6300308 (2001-10-01), Schroit
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6783760 (2004-08-01), Thorpe et al.
patent: 6806354 (2004-10-01), Schroit
patent: 6818213 (2004-11-01), Thorpe et al.
patent: 2002/0025319 (2002-02-01), Brams
patent: 2003/0004097 (2003-01-01), Schroit
patent: 2003/0129223 (2003-07-01), Wartchow et al.
patent: 2003/0133972 (2003-07-01), Danthi et al.
patent: 2003/0194400 (2003-10-01), Liu et al.
patent: 0 255 424 (1988-02-01), None
patent: 0 260 148 (1988-03-01), None
patent: 0 266 993 (1988-05-01), None
patent: 0 359 347 (1990-03-01), None
patent: 0 278 776 (1997-05-01), None
patent: 0 669 988 (2003-09-01), None
patent: WO 88/07543 (1988-10-01), None
patent: WO 90/03801 (1990-04-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 91/05806 (1991-05-01), None
patent: WO 91/07187 (1991-05-01), None
patent: WO 91/07941 (1991-06-01), None
patent: WO 92/01470 (1992-02-01), None
patent: WO 92/12729 (1992-08-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 95/19791 (1995-07-01), None
patent: WO 95/27903 (1995-10-01), None
patent: WO 95/34315 (1995-12-01), None
patent: WO 96/01653 (1996-01-01), None
patent: WO 96/17618 (1996-06-01), None
patent: WO 97/17084 (1997-05-01), None
patent: WO 98/04294 (1998-02-01), None
patent: WO 98/29453 (1998-07-01), None
patent: WO98/29453 (1998-07-01), None
patent: WO 98/43678 (1998-10-01), None
patent: WO 01/54723 (2001-08-01), None
patent: WO 03/033514 (2003-04-01), None
patent: WO 03/035688 (2003-05-01), None
Huang et al, Science;275:547-550, 1997.
Dvorak et al, Cancer cells;3(3):77-85, 1991.
Diaz et al.; “Synthesis of Disulfide-Containing Phospholipid Analogs for the Preparation of Head Group-Specific Lipid Antigens: Generation of Phosphatidylserine Antibodies;”Bioconjugate Chem.; 9:250-254, 1998.
Kasina et al.; “Preformed Chelate TC-99m Radiolabeling of r-Annexin V for Arterial Thrombus Imaging;”Nucl. Med.; vol. 37, No. 5, 29P.
Rauch and Janoff; “Antibodies Against Phospholipids Other than Cardiolipin: Potential Roles for Both Phospholipid and Protein;”Lupus; 5:498-502, 1996.
Sarrot-Reynauld and Massot; “Antiphospholipid Antibodies Paraneoplastic Syndrome Revealing Prostatic Cancer;”Lupus; vol. 5, No. 5, pp. 528, 1996.
Thorpe et al.; “Tumor Infarction: Immunoconjugates that Coagulate the Vasculature of Solid Tumors;”Proceedings of the Annual Meeting of the American Association for Cancer Research; 36:488, 1995.
van Heerde et al.; “Binding of Recombinant Annexin V to endothelial Cells: Effect of Annexin V Binding on Endothelial-Cell-Mediated Thrombine Formation;”Biochem.; 302:305-312, 1994.
International Search Report for PCT/US99/15668, mailed Dec. 29, 1999.
Ferro et al., “Coexistence of Anti-Phospholipid Antibodies and Endothelial Perturbation in Systemic Lupus Erythematosus Patients with Ongoing Prothrombotic State,”Circulation, 95(6):1425-1432, 1997.
Fishman et al., “Autoimmunity and Cancer—Beneficial Relationships: a new Concept for the Production of Human Monoclonal Antibodies (Review),”International Journal of Onocology, 10:901-904, 1997.
Tobelem, “Les Anticorps Antiphospholipides: Specificite et Mechanisme d'Action,”Ann. Med. Interne, 141:257-260, 1990.
International Search Report for PCT/US99/15660, mailed Jan. 26, 2000.
Maisonpierre et al., “Angiopoietin-2, a Natural Antagonist for Tie2 that DisruptsIn VivoAngiogenesis,”Research Articles, 277:55-60, 1997.
International Search Report for PCT/US00/18779, mailed Oct. 4, 2000.
Co-pending U.S. Appl. No. 09/351,149; Entitled: “Cancer Treatment Using Angiopoietins Targeted to Aminophospholipids,” filed Jul. 10, 2000.
Andre et al., “Angiogenese Tumorale: Physiopathologic, Valeur Pronostique et Perspectives Therapeutiques,”Rev. Med. Interne.19:904-913, 1998.
Thiagarajan and Benedict, “Inhibition of Arterial Thormbosis by Recombinant Annexin V in a Rabbit Carotid Artery Injury Model,”Circulation, 96(7):2339-2347, 1997.
Abaza and Atassi, “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetrmined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin,”J. Protein Chemistry, 11(5):433-444, 1992.
Attwood, “The Babel of Bioinformatics,”Science, 290(5491):471-473, 2000.
Mikayama et al., “Molecular Cloning and Functional Expression of a cDNA Encoding Glycosylation-Inhibiting Factor,”Proc. Natl. Acad. Sci. USA, 90:10056-10060, 1993.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,”In, The Protein Folding Problem and Tertiary Structure Prediction, Eds., Marz & LaGrand, pp. 492-495, 1994.
Voet et al., “Chemical Evolution,”In, Biochemistry I, Voet & Voet, pp. 126-234, 1990.
Skolnick and Fetrow, “From genes to protein structure and function: novel applications of computational approaches in the genomic era,”Trends in Biotech, 2000.
Bach et al., “Factor VII Binding to Tissue Factor in Reconstituted Phospholipid Vesicles: Induction of Cooperativity by Phosphatidylserine,”Biochemistry, 25:4007-4020, 1986.
Bodey et al, “Failure of Cancer Vaccines: The Significant Limitations of the Approach to Immunotherapy,”Anticancer Res., 20:2665-2676, 2000.
Colman, “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,”In A Structural Views of Immune Recognition by Antibodies, 33-36, 1994.
Kuby et al.,Immunology, Second Edition, 86-96, 1944.
Spitler, “Cancer Vaccines: The Interferon Analogy,”Cancer Biotherapy, 10(1):1-3, 1995.
Katsuragawa et al., &#
Brekken Rolf A.
Ran Sophia
Thorpe Philip E.
Board of Regents , The University of Texas System
Fussey Shelley P. M.
Padmanabhan Sreeni
Sharareh Shahnam
LandOfFree
Cancer treatment kits comprising therapeutic conjugates that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatment kits comprising therapeutic conjugates that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment kits comprising therapeutic conjugates that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3647224